News Daiichi and AZ pull Dato-DXd filing in Europe too AstraZeneca and Daiichi Sankyo have decided to voluntarily withdraw their EU marketing application for Dato-DXd in lung cancer.
News AZ gets EU okay for Tagrisso in early-stage lung cancer AstraZeneca's EGFR inhibitor Tagrisso has become the first drug in the class to be approved in the EU for a form of early-stage lung cancer.
News MSD eyes June verdict for paediatric RSV antibody The FDA has started a review of MSD's RSV antibody clesrovimab, a potential rival to Beyfortus, with a verdict due in the middle of next year.
Oncology Sponsored 12 Questions with Mimi Huizinga Dr Mimi Huizinga is Vice President, Oncology Medical Affairs, Lung Cancer at AstraZeneca.
News Lynparza boosts long-term survival in early breast cancer A single year of adjuvant treatment with AstraZeneca and MSD's PARP inhibitor Lynparza is still providing a survival benefit six years later.
News MSD gets first positive trial of Keytruda/Lynparza combo After a string of trial failures, MSD claims a partial win for Keytruda and Lynparza in advanced epithelial ovarian cancer.
Digital The TechBio way: Brendan Frey talks genomics, AI, and RNA pharmaphorum speaks with Brendan Frey, founder and chief innovation officer of Deep Genomics, an AI-first TechBio organisation.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face
